IRCT20171018036870N2 IRCT 2018-08-26 Yazd University of Medical Sciences Combined metformin and sitagliptin effect on expression levels of proteins involved in insulin resistance in adipose tissue of diabetic patients Combined metformin and sitagliptin effect on expression levels of proteins involved in insulin resistance (IRS-1/PI3K/Akt/mTOR/GLUT4) in adipose tissue of diabetic patients 2018-02-04 anticipated 15 Complete https://irct.ir/trial/27444 interventional Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment. 2 Type 2 Diabetes Mellitus. Intervention 1: Intervention group: We have two intervention groups: Group 1: This group only receive metformin for 3 months. Metformin: Branded metformin hexal, 500 mg (metformin hydrochloride), Made in Germany(Hexal AG), twice daily dosing, morning after breakfast, and evening after dinner. Intervention 2: Intervention group: Group 2: This group receive metformin and sitaglyptin simultaneously for 3 months.Metformin: Branded metformin hexal, 500 mg (metformin hydrochloride), Made in Germany(Hexal AG), twice daily dosing, morning after breakfast, and evening after dinner. Sitaglyptin: Branded Januvia, 50mg manufactured by England, licensed to Merck, twice a day, in the morning after breakfast and at night after dinner. Intervention 3: Control group: 5 non-immune non-insulin-dependent non-insulin-dependent individuals. These people do not use any drugs. Yes - There is a plan to make this available What will be shared: If individual data is available to participants without a first and last name, access to them is possible When: forever To whom: All medical field researchers Conditions: Only for observation is allowed. Where to obtain: Visit Iranian Randomized Clinical Trial How to obtain: Users should certainly mention the name of the Iranian Randomized Clinical Trials as a source. Comments: